C9073

Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Terminated March 31, 2021.

Notice

HCPCS C9073 terminated on March 31, 2021.

Short Description

Brexucabtagene autoleucel ca

HCPCS Coverage Code

D = Special coverage instructions apply

HCPCS Action Code

N = No maintenance for this code

HCPCS Action Effective Date

April 01, 2021

HCPCS Code Added Date

January 01, 2021

HCPCS Termination Date

March 31, 2021

HCPCS Pricing Indicator Code

53 = Statute

HCPCS Multiple Pricing Indicator Code

A = Not applicable as HCPCS priced under one methodology

HCPCS Statute Number

1833(T)

HCPCS Cross Reference Code

Q2053

HCPCS Type Of Service Code

9 = Other medical items or servicesF = Ambulatory surgical center (facility usage for surgical services)

C9073

Notice

Short Description

HCPCS Coverage Code

HCPCS Action Code

HCPCS Action Effective Date

HCPCS Code Added Date

HCPCS Termination Date

HCPCS Pricing Indicator Code

HCPCS Multiple Pricing Indicator Code

HCPCS Statute Number

HCPCS Cross Reference Code

HCPCS Type Of Service Code

HCPCS Anesthesia Base Unit Quantity